MedTrace Logo

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

NCT06179069 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 339

Last updated 2026-04-03

No results posted yet for this study

Summary

An open-label, multicenter study of ZL-1310 as a single agent and in combination with Atezolizumab (with and without Carboplatin) to evaluate the safety, efficacy, and pharmacokinetics in subjects with small cell lung cancer

Conditions

Interventions

DRUG

ZL-1310

Drug: ZL-1310

DRUG

Atezolizumab

Drug Atezolizumab

DRUG

Carboplatin

Drug Carboplatin

Sponsors & Collaborators

  • Zai Lab (US) LLC

    collaborator INDUSTRY

  • Zai Lab (Shanghai) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-23
Primary Completion
2027-05-30
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United States
  • China
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06179069 on ClinicalTrials.gov